



## Erratum to: Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer

Mohammad Jaber<sup>1</sup> · Miriam Maoz<sup>1</sup> · Arun Kancharla<sup>1</sup> · Daniel Agranovich<sup>1</sup> · Tamar Peretz<sup>1</sup> · Sorina Grisar-Granovsky<sup>2</sup> · Beatrice Uziely<sup>1</sup> · Rachel Bar-Shavit<sup>1</sup>

Published online: 30 November 2016  
© Springer International Publishing 2016

**Erratum to: Cell. Mol. Life Sci. (2014)**  
**71:2517–2533**  
**DOI 10.1007/s00018-013-1498-7**

In the published article, duplicated or inverted gel sections had been used in the Figs. 1Ai, Aii, D, 2Aii, 4B and 6C. In agreement with the Editor-in-Chief the experiments were repeated and the same results obtained. The primary data from the repeated experiments can be found below.

---





The online version of the original article can be found under doi:[10.1007/s00018-013-1498-7](https://doi.org/10.1007/s00018-013-1498-7).

---

✉ Rachel Bar-Shavit  
Rachelbar@ekmd.huji.ac.il

<sup>1</sup> Sharett-Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, 91120 Jerusalem, Israel

<sup>2</sup> Department of Obstetrics and Gynecology, Shaare-Zedek and Hadassah-Hebrew University Medical Centers, POB 12000, 1120 Jerusalem, Israel


Silencing of *hPar2* inhibits the co-IP of Etk/Bmx with PAR<sub>1</sub> C-tail**B** Silencing of *hPar2* inhibits the co-IP of Akt with PAR<sub>1</sub> C-tail and its phosphorylation**C** Levels of transfection and silencing in the MCF-7 clones**D** Silencing of *hPar2* inhibits selectively PAR<sub>1</sub> activated co-association of Akt with PAR<sub>1</sub> C-tail in MDA-MB-231 cells

Antibodies used: anti PAR<sub>1</sub> BioLegend clone N2-11# 659102 San Diego, Ca  
anti Akt Cell Signaling #9272  
anti β-actin Sigma A5441



**Explanatory note:** Total cell lysate is not part of the immunoprecipitation (IP) assay. It serves as an internal indicator for the size of Akt on the gel.

◀ **Fig. 1** Silencing of *hPar2* inhibits association of key signaling partners with the PAR<sub>1</sub> C-tail. **Ai** MCF7 cells stably over-expressing HA-*hPar1* and T7-Etk/Bmx were infected with a lentiviral vector driving either *shRNA-hPar2* expression or a scrambled *shRNA-hPar2* and cultured with or without thrombin activation (1 U/ml) (**Ai**) or the PAR<sub>1</sub> selective ligand, TFLLRN (100 μM) (**Aii**). Cell lysates were collected at the indicated times and immunoprecipitated using anti-HA antibodies. Immunoprecipitates were separated on SDS-PAGE and Western blotted with anti-T7 antibody to detect T-7 tagged Etk/Bmx. Maximal association of Etk/Bmx is seen after 10 min of thrombin treatment in cells without *hPar2* silencing (scrambled *shRNA-hPar2*); but is not detectable in cells infected with *shRNA-Par2*. A specific, Etk/Bmx is seen associated after 5', 10', 15', and 20 min following TFLLRN activation in cells expressing both HA-*hPar1* and endogenous *hPar2* (scrambled *shRNA-hPar2*). In contrast, the Etk/Bmx association is not detected in the presence of *shRNA-hPar2*. **B** Silencing *hPar2* inhibits thrombin-induced association between PAR<sub>1</sub> and Akt. MCF7 clones overexpressing HA-*hPar1*, with *shRNA hPar2* silencing (*right*), or scrambled *shRNA hPar2* (*left*), were treated with thrombin for the indicated times. Cell lysates were immunoprecipitated with anti-HA to precipitate HA-PAR<sub>1</sub> and analyzed by Western blot with anti-Akt antibodies, followed by antibodies to phosphorylated Akt (pAkt). HA-PAR<sub>1</sub> serves as a loading control. **C** PAR<sub>2</sub> expression in the MCF7 clone (expressing *hPar1*, *hPar2*, and *etk/bmx*) with and without *shRNA* silencing as compared with a housekeeping gene GAPDH. **D** Silencing *hPar2* inhibits TFLLRN PAR<sub>1</sub> activation in MDA-MB-231 cells. MDA-MB-231 cells expressing high endogenous levels of both PAR<sub>1</sub> and PAR<sub>2</sub> show a similar pattern (to MCF7 cells) of selective PAR<sub>1</sub> inhibition in the presence of *sh-RNA hPar2*. TFLLRN activation induces the co-IP between PAR<sub>1</sub> and Akt immediately after 2', 5', 10', and 20' activation (scrambled *sh-RNA hPar2*). In the presence of *sh-RNA hPar2*, this association is markedly inhibited. β-actin serves as a loading control

*shRNA hPar2* significantly attenuates thrombin induced colony formation in soft agar







a,b - control (with no activation)  
 c- thrombin activation  
 d- TFLLRN activation  
 e- *shRN hPar2* and thrombin activation  
 f- *shRNA hPar2* and TFLLRN  
 g- scrambled *hPar2* and thrombin activation  
 h- *sh-hPar1* and thrombin activation  
 i,j - SLIGKV PAR<sub>2</sub> activation




**Explanatory note:** We analyzed silencing in 2 clones *sh hPar1* and *sh hPar2* therefore we show now GAPDH levels for each clone.

*shRNA* silencing of *hPar2* markedly inhibits PAR<sub>1</sub> induced invasion




◀ **Fig. 2 Ai** Silencing *hPar2* in a breast cancer cell line inhibits thrombin- or TFLLRNPNDK-induced colony formation in soft agar.  $5 \times 10^3$  MDA-MB-231 cells, either uninfected (*a, b*) or infected with virus expressing *shRNA-GFP-hPar2* (*e, f*), were plated in soft agar and activated by thrombin (*e*) or TFLLRNPNDK (*f*). Uninfected cells were treated with thrombin (*c*) or TFLLRN (*d*) as also with SLIGKV (*i, j*). Controls of either scrambled *shRNA hPar2* with thrombin activation (*g*) and *shRNA hPar1* with thrombin activation (*h*) were shown as well. After 12 days, live images were collected using a Zeiss microscope at  $\times 20$  magnification. In uninfected cells, large colonies formed following treatment with either thrombin (*c*) and somewhat smaller with TFLLRNPNDK (*d*). MDA-MB-231 cells infected with *sh-GFP-hPar2* formed only very small colonies after thrombin (*e*) or TFLLRNPNDK (*f*) treatment. Cells containing *sh-hPar2* are visualized by GFP fluorescence (*e*). The colonies formed under different conditions were compared with control non-activated, non-treated cells (control; *a, b*). The colonies formed in the presence of *shRNA-hPar1* and after thrombin activation is significantly smaller (panel *h*) than colonies formed after thrombin activation (*c*). Scrambled *shRNA-hPar2* had no effect on the colonies formed (panel *g*). Comparable colony size is obtained by SLIGKV PAR<sub>2</sub> activation (*i, j*) as found by TFLLRNPNDK (*d*). Images shown are representative of three independent experiments. **Aii** RT-PCR analysis of *hPar1* and *hPar2* mRNA expression before and after *shRNA* silencing. GAPDH levels were analyzed as a control. **Aiii** Histogram shows mean  $\pm$  SE of triplicate values from three independent experiments. Post hoc evaluation of multiple comparison (ANOVA Tukey HSD) showed a *p* value of 0.004 within groups. The mean difference is significant at the 0.05 level. For ANOVA evaluation we used IBM SPSS 20.0 software. **Bi** Silencing *hPar2* in MDA-MB-231 cells inhibits TFLLRN PAR<sub>1</sub> invasion. Matrigel invasion in the presence of *shRNA-hPar2*-infected cells as compared with scrambled *shRNA*. While TFLLRN specific activation of PAR<sub>1</sub> induces Matrigel invasion in MDA-MB-231 cells, this was attenuated in the presence of *shRNA-hPar2*-infected cells. In-contrast, no effect was observed when a scrambled *shRNA* was utilized to infect the cells, demonstrating a markedly induced Matrigel invasion similar to non-treated activated parental MDA-MB-231 cells. **Bii** Histograms represents quantification of the cells/HPF invaded the Matrigel layer. Unpaired Student's *t* test was used. This experiment is a representative of three independent experiments performed in triplicates. **Biii** Silencing *hPar1* in MDA-MB-231 cells did not inhibit PAR<sub>2</sub> function. In MDA-MB-231 cells silenced for *hPar1*, thrombin activation resulted with a low level of Matrigel invasion. In-contrast, SLIGKV PAR<sub>2</sub> activation under conditions of *sh-hPar1* silencing, resulted with potent Matrigel invasion. **Biv** Histograms represents quantification of the cells/HPF invaded the Matrigel layer in *shRNA hPar1* silenced cells. Unpaired Student's *t* test was used. This experiment is a representative of three independent experiments performed in triplicates

**A** Co-localization of PAR<sub>1</sub> and PAR<sub>2</sub> in HEK293T cells: Confocal analyses



**B** Co-immunoprecipitation of PAR<sub>1</sub> and PAR<sub>2</sub> in HEK 293 cells




**Explanatory note:** HEK293 cells were transfected with: YFP-*hPar2*, HA-*hPar1* and GFP-CXCR4 plasmids. The size of CXCR4 is ~39kDa, GFP is 27 kDa resulting with total size of ~66 kDa. The size of PAR<sub>2</sub> plus YFP (26kDa), as seen in the original gel ( see slide number 11) is approximately 63kDa. Under the gel condition used in the repeated experiment we could not detect the ~3kDa difference. The GFP detected two band. We refer to the lower band as both CXCR4 –GFP and PAR<sub>2</sub>-YFP. The upper band may detect higher forms of PAR<sub>2</sub> (e.g., possibly a glycosylated form).

**Fig. 4** Co-localization of PAR<sub>1</sub> and PAR<sub>2</sub>. **A** Confocal immunofluorescence analysis. HEK-293T cells were transfected with both HA-*hPar1* and YFP-*hPar2*. After 24 h, the cells were serum deprived for an additional 24 h then activated with thrombin for 5 min followed by fixation with cold methanol. PAR<sub>2</sub> was visualized by direct fluorescence (a) and PAR<sub>1</sub> was visualized by immunostaining with anti HA-antibodies followed by Cy3-conjugated IgG secondary antibodies (b). Merge staining for both PAR<sub>1</sub> and PAR<sub>2</sub> revealed co-localization confined to the cell membrane (d). For reference, staining of cell nuclei with Draq5 is shown (c). The bottom panel highlights the expression of YFP-*hPar2* and HA-*hPar1* on the cell membrane prior to activation (i, ii). Significant co-localization recapitulated by merge fluorescence is observed following five minutes thrombin activation (iv). This is detected as compared with cell nuclei staining (iii) and phase-contrast analysis (v). The percent

of positive cells for HA-*hPar1* was 58 % ± 1.2 and for YFP-*hPar2* were 55 % ± 1.86; PAR<sub>1</sub>-PAR<sub>2</sub> merge was observed in 45 % ± 2.1. **B** PAR<sub>1</sub> and PAR<sub>2</sub> co-immunoprecipitate. HEK 293T cells expressing either HA-*hPar1*, YFP-*hPar2* or GFP-CXCR4 were treated with thrombin for 10 min and lysed. Cell lysates were then immunoprecipitated before (–) and after (+) thrombin activation by anti HA or IgG, resolved by SDS-PAGE and immunoblotted as indicated (by anti-GFP). While no specific complex is formed when CXCR4 and PAR<sub>1</sub> were co-IP (following 10-min thrombin activation), a specific complex is observed between PAR<sub>1</sub> and PAR<sub>2</sub> following activation. No specific band is seen when IgG were applied in the immunoprecipitation assay. Expression of CXCR4, PAR<sub>2</sub> (as indicated by anti-GFP, first lane), and PAR<sub>1</sub> (as shown by anti-HA) were shown as controls for transfection efficiency. The figure shown is a representative of three independent experiments

Impaired tumor development in the presence of truncated non-functional PAR<sub>2</sub> and PAR<sub>1</sub>



**Fig. 6** Impaired tumor development in the presence of PAR<sub>1</sub> and truncated PAR<sub>2</sub>. Stable clones of HU cells expressing either *hPar2* or *hPar1* and *hPar2*, or *hPar1* and truncated *hPar2* were injected subcutaneously into nude mice ( $2 \times 10^6$  cell/mouse). Parental non-transfected HU cells were used as a control. **A** Tumor morphological appearance. Mice injected either with *hPar1* and *hPar2* or *hPar2* developed tumors at the sites of injection. In-contrast, mice inoculated with *wt hPar1* and a truncated form of *hPar2* did not develop or developed very little tumors (*a*). By the end of the experiment (e.g.,

35 days) the mice were killed and the tumors were excised, measured, and weighed ( $n = 4$ /per group). **B** Mouse tumor growth curve in nude mice. Tumors were excised, weighed and measured at the indicated times and tumor volume (mm<sup>3</sup>) was calculated. *Error bars* show SD; \* indicates  $p < 0.006$ . Data shown are representative of three experiments performed. **C**, *ii* RT-PCR analyses of the indicated clones (*a* and *b*; two different clones) show the expression of PAR<sub>1</sub> and PAR<sub>2</sub>, truncated PAR<sub>2</sub> and the prime signal protein Etk/Bmx